参考文献/References:
[1] Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC)[J]. J Hypertens, 2013,31(7):1281-1357.
[2] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华高血压杂志, 2011, 19:701-743.
[3] Fox KM.European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double blind, placebo controlled, multicentre trial(the EUROPA study)[J]. Lancet,2003,362(9386):782-788.
[4] Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older[J]. N Engl J Med,2008,358:1887-1898.
[5] Dahl öf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA): a multicentre randomized controlled trial[J]. Lancet,2005,366(9489):895-906.
[6] Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients[J]. N Engl J Med,2008,359(23):2417-2428.
[7] ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events[J]. N Engl J Med,2008,358(15):1547-1559.
[8] Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents[J]. JAMA,2003,289(19):2534-2544.
[9] Petrella R, Michailidis P. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management[J]. Clin Ther,2011,33(9):1190-1203.
[10] Barrios V, Escobar C. Candesartan in the treatment of hypertension: what have we learnt in the last decade?[J]. Expert Opin Drug Saf,2011,10(6):957-968.
[11] Solis-Herrera C, Triplitt CL, Lynch JL. Nephropathy in youth and young adults with type 2 diabetes[J]. Curr Diabetes Rep,2014,14(2):1-9.
[12] Schmieder RE, Schwertfeger M, Bramlage P. Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice[J]. Vasc Health Risk Manag,2009,5:991-1000.
[13] Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study(LIFE): a randomised trial against atenolol[J]. Lancet,2002,359:995-1003.
[14] Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly(SCOPE):principal results of a randomized double-blind intervention trial[J]. J Hypertens,2003,21:875-886.
[15] Parving HH, Lehnert H, Bröchner-Mortensen J,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[J]. N Engl J Med, 2001,345:870-878.
[16] Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes[J].N Engl J Med, 2001,345(12):851-860.